Naringenin confers neuroprotection in a cuprizone-induced mouse model of multiple sclerosis with upregulation of PPAR-γ expression
Journal of Pharmacy and Pharmacology · 2026
DOI: 10.1093/jpp/rgag113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2026. Verfasst von Shereen F Behairy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Nutritional Psychology, San José, CA 95129, United States. Hauptthemen laut MEDLINE: Flavanones, PPAR gamma, Multiple Sclerosis, Neuroprotective Agents. Die Arbeit nennt 69 Literaturangaben.
Abstract (Originalsprache)
Objectives
To investigate the effects of naringenin on pathological, molecular, and behavioural alterations in a cuprizone-induced mouse model of demyelination, with particular emphasis on peroxisome proliferator-activated receptor (PPAR) gamma expression, NOD-like receptor family pyrin domain-containing 3 immunoreactivity, and molecular markers of myelin integrity, inflammation, and apoptosis.
Methods
Mice were allocated to four groups: control, naringenin alone, cuprizone, and cuprizone plus naringenin. Demyelination was induced with cuprizone-containing chow, and naringenin was administered orally for three weeks. Motor performance and biochemical, molecular, and histological changes were evaluated using established behavioural, immunological, molecular, and histological techniques. Key findings Naringenin improved motor deficits, increased myelin basic protein expression, reduced tumour necrosis factor-alpha, interleukin-1 beta, cyclooxygenase-2, prostaglandin E2, and nuclear factor kappa B p65 levels, and shifted apoptotic signalling towards cell survival by decreasing Bcl-2-associated X and increasing B-cell lymphoma 2 expression. Naringenin also increased PPAR gamma expression while reducing NOD-like receptor family pyrin domain-containing 3 immunoreactivity and suppressor of cytokine signalling 3 expression.
Conclusions
Naringenin attenuated cuprizone-induced brain inflammatory responses, apoptosis, and myelin injury, with findings consistent with modulation of PPAR gamma expression and NOD-like receptor family pyrin domain-containing 3-associated neuroinflammatory responses. These findings support further preclinical evaluation of naringenin for multiple sclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Nutritional Psychology, San José, CA 95129, United States.
- Department of Pharmacology and Toxicology, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University of Science and Technology (MUST), Giza 12566, Egypt.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo 12613, Egypt.
- Clinical Pharmacy Department, School of Pharmacy, Newgiza University, Giza 12563, Egypt.
ORCID-Profile: Shereen F Behairy, Mohamed I Fahmy, Rabab H Sayed
Zitieren
APA
Behairy, S. F., Fahmy, M. I., Sayed, R. H., & El-Yamany, M. F. (2026). Naringenin confers neuroprotection in a cuprizone-induced mouse model of multiple sclerosis with upregulation of PPAR-γ expression. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgag113
Vancouver
Behairy SF, Fahmy MI, Sayed RH, El-Yamany MF. Naringenin confers neuroprotection in a cuprizone-induced mouse model of multiple sclerosis with upregulation of PPAR-γ expression. Journal of Pharmacy and Pharmacology. 2026. doi:10.1093/jpp/rgag113
BibTeX
@article{Behairy2026,
author = {Behairy, Shereen F and Fahmy, Mohamed I and Sayed, Rabab H and El-Yamany, Mohammed F},
title = {Naringenin confers neuroprotection in a cuprizone-induced mouse model of multiple sclerosis with upregulation of PPAR-γ expression},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
doi = {10.1093/jpp/rgag113}
}
EUVIMED